Laura Xicota1, Joan Rodríguez2, Klaus Langohr3, Montserrat Fitó4, Mara Dierssen5, Rafael de la Torre6. 1. Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Cellular & Systems Neurobiology, Systems Biology Program, Centre for Genomic Regulation, The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain. 2. Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain. 3. Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Department of Statistics and Operations Research, Universitat Politècnica de Catalunya/BarcelonaTech, Barcelona, Spain. 4. Cardiovascular Risk and Nutrition Research Group, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; CIBER Fisiopatología Obesidad y Nutrición, Instituto Salud Carlos III, Madrid, Spain. 5. Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Cellular & Systems Neurobiology, Systems Biology Program, Centre for Genomic Regulation, The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; CIBER de Enfermedades Raras, Instituto Salud Carlos III, Madrid, Spain. Electronic address: mara.dierssen@crg.eu. 6. Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; CIBER Fisiopatología Obesidad y Nutrición, Instituto Salud Carlos III, Madrid, Spain. Electronic address: RTorre@imim.es.
Abstract
BACKGROUND & AIMS:Individuals with Down syndrome (DS) have higher rates of obesity. In the general population green tea extracts, and in particular epigallocatechin gallate (EGCG), have been studied for their antiobesogenic effects. The aim of this study is to elucidate the effect of EGCG on body weight in young DS adults and whether it could be related to changes in lipid profile. METHODS: In the context of a double-blind phase II clinical trial comparing the effect of EGCG to that of placebo, the body composition of 77 young adults with DS was analyzed through bioelectrical impedance analysis. Lipids were analyzed using standard laboratory procedures. The factors tested in the ANCOVA model for the differences from baseline were treatment, sex as well as their interaction as independent variables. Baseline values were included in the models as covariates. RESULTS: Individuals receiving placebo showed an increase in body weight and body mass index (BMI) that was not detected in those with EGCG treatment. EGCG effect on body composition was mainly observed in males, with significant differences between the EGCG and the placebo group after 12 months for weight (estimated adjusted mean difference (AMD) = -2.34, 95% CI = [-4.21, -0.48]; p = 0.015) and body fat (estimated AMD = -1.23, 95% CI = [-2.43,-0.04], p = 0.043). The changes detected in body composition were associated with changes in lipid profile. CONCLUSIONS: Our results suggest that EGCG could have a modest beneficial effect on weight management in DS. Furthermore, EGCG has also a sex-dependent effect on lipid profile that is related to changes in body mass and composition.
RCT Entities:
BACKGROUND & AIMS: Individuals with Down syndrome (DS) have higher rates of obesity. In the general population green tea extracts, and in particular epigallocatechin gallate (EGCG), have been studied for their antiobesogenic effects. The aim of this study is to elucidate the effect of EGCG on body weight in young DS adults and whether it could be related to changes in lipid profile. METHODS: In the context of a double-blind phase II clinical trial comparing the effect of EGCG to that of placebo, the body composition of 77 young adults with DS was analyzed through bioelectrical impedance analysis. Lipids were analyzed using standard laboratory procedures. The factors tested in the ANCOVA model for the differences from baseline were treatment, sex as well as their interaction as independent variables. Baseline values were included in the models as covariates. RESULTS: Individuals receiving placebo showed an increase in body weight and body mass index (BMI) that was not detected in those with EGCG treatment. EGCG effect on body composition was mainly observed in males, with significant differences between the EGCG and the placebo group after 12 months for weight (estimated adjusted mean difference (AMD) = -2.34, 95% CI = [-4.21, -0.48]; p = 0.015) and body fat (estimated AMD = -1.23, 95% CI = [-2.43,-0.04], p = 0.043). The changes detected in body composition were associated with changes in lipid profile. CONCLUSIONS: Our results suggest that EGCG could have a modest beneficial effect on weight management in DS. Furthermore, EGCG has also a sex-dependent effect on lipid profile that is related to changes in body mass and composition.
Authors: Raza Jamal; Jonathan LaCombe; Roshni Patel; Matthew Blackwell; Jared R Thomas; Kourtney Sloan; Joseph M Wallace; Randall J Roper Journal: PLoS One Date: 2022-02-23 Impact factor: 3.752